'''Pediatric ependymomas''' are similar in nature to the adult form of [[ependymoma]] in that they are thought to arise from [[radial glial cell]]s lining the [[ventricular system]]. However, they differ from adult [[ependymoma]]s in which [[gene]]s and [[chromosome]]s are most often affected, the region of the brain they are most frequently found in, and the [[prognosis]] of the patients.  Children with certain [[hereditary disease]]s, such as [[neurofibromatosis type II|neurofibromatosis type II (NF2)]], have been found to be more frequently afflicted with this class of tumors, but a firm [[genetics|genetic]] link remains to be established. [[Symptom]]s associated with the development of pediatric ependymomas are varied, much like [[symptom]]s for a number of other pediatric [[brain tumor]]s including vomiting, headache, irritability, [[lethargy]], and changes in [[gait]]. Although younger children and children with invasive tumor types generally experience less favorable outcomes, total removal of the tumors is the most conspicuous [[prognostic]] factor for both survival and [[relapse]].

== Basic biology ==

=== Cell of origin ===
Ependymomas are believed to arise from [[radial glial cell]]s. Tumorspheres derived from [[ependymoma]]s display a radial-glial like [[phenotype]], expressing [[neuron]]al stem cell markers [[CD133]] and [[nestin (protein)|nestin]], as well as radial glial specific markers RC2 and brain lipid binding protein (BLBP/[[FABP7]]). Tumorspheres with radial glial characteristics form tumors in orthotopic mouse [[xenograft]]s, suggesting radial glial as cell of origin for [[ependymoma]]s.<ref name="Pmid_f">{{cite journal |pmid=16226707 |year=2005 |last1=Taylor |first1=MD |last2=Poppleton |first2=H |last3=Fuller |first3=C |last4=Su |first4=X |last5=Liu |first5=Y |last6=Jensen |first6=P |last7=Magdaleno |first7=S |last8=Dalton |first8=J |last9=Calabrese |first9=C |title=Radial glia cells are candidate stem cells of ependymoma |volume=8 |issue=4 |pages=323–35 |doi=10.1016/j.ccr.2005.09.001 |journal=Cancer Cell}}</ref><ref>{{cite journal |pmid=11133151 |year=2001 |last1=Hartfuss |first1=E |last2=Galli |first2=R |last3=Heins |first3=N |last4=Götz |first4=M |title=Characterization of CNS precursor subtypes and radial glia |volume=229 |issue=1 |pages=15–30 |doi=10.1006/dbio.2000.9962 |journal=Developmental biology}}</ref>

===Inheritance===
A number of [[genetics|genetic]] syndromes are associated with the development of [[ependymoma]], including [[neurofibromatosis type II]] (NF2), [[Turcot syndrome]] B, and [[MEN1]] syndrome.  However, [[gene]] [[mutation]]s linked to the [[family|familial]] syndromes are rarely found in [[sporadic cancer|sporadic]] cases of [[ependymoma]].<ref name="Pmid_i">{{cite journal |pmid=18676356 |year=2008 |last1=De Bont |first1=JM |last2=Packer |first2=RJ |last3=Michiels |first3=EM |last4=Den Boer |first4=ML |last5=Pieters |first5=R |title=Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective |volume=10 |issue=6 |pages=1040–60 |doi=10.1215/15228517-2008-059 |pmc=2719002 |journal=Neuro-oncology}}</ref>  For example, [[NF2 (gene)|NF2]] [[mutation]]s have rarely been observed in [[ependymoma]]s and [[MEN1]] [[mutation]]s have only been found in a small number of cases of [[ependymoma]] recurrences.<ref name="Pmid_d">{{cite journal |pmid=8261460 |year=1994 |last1=Rubio |first1=MP |last2=Correa |first2=KM |last3=Ramesh |first3=V |last4=MacCollin |first4=MM |last5=Jacoby |first5=LB |last6=Von Deimling |first6=A |last7=Gusella |first7=JF |last8=Louis |first8=DN |title=Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas |volume=54 |issue=1 |pages=45–7 |journal=Cancer Research}}</ref><ref>{{cite journal |pmid=8805149 |year=1996 |last1=Birch |first1=BD |last2=Johnson |first2=JP |last3=Parsa |first3=A |last4=Desai |first4=RD |last5=Yoon |first5=JT |last6=Lycette |first6=CA |last7=Li |first7=YM |last8=Bruce |first8=JN |title=Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas |volume=39 |issue=1 |pages=135–40 |journal=Neurosurgery |doi=10.1097/00006123-199607000-00026}}</ref><ref>{{cite journal |pmid=10433955 |year=1999 |last1=Ebert |first1=C |last2=Von Haken |first2=M |last3=Meyer-Puttlitz |first3=B |last4=Wiestler |first4=OD |last5=Reifenberger |first5=G |last6=Pietsch |first6=T |last7=Von Deimling |first7=A |title=Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas |volume=155 |issue=2 |pages=627–32 |pmc=1866851 |doi=10.1016/S0002-9440(10)65158-9 |journal=The American journal of pathology}}</ref><ref>{{cite journal |pmid=20594149 |year=2010 |last1=Buccoliero |first1=AM |last2=Castiglione |first2=F |last3=Degl'innocenti |first3=DR |last4=Sardi |first4=I |last5=Genitori |first5=L |last6=Taddei |first6=GL |title=Merlin expression in pediatric anaplastic ependymomas real time PCR study |volume=29 |issue=4 |pages=245–54 |doi=10.3109/15513811003789644 |journal=Fetal and pediatric pathology}}</ref>

===Oncogenic lesions===
''[[ERBB2]]'', ''[[ERBB4]]'', and [[human telomerase reverse transcriptase]] (''[[TERT]]'') [[gene expression]] promote tumor cell proliferation, contributing to aggressive tumor behavior.<ref name="Pmid_h">{{cite journal |pmid=12374672 |year=2002 |last1=Gilbertson |first1=RJ |last2=Bentley |first2=L |last3=Hernan |first3=R |last4=Junttila |first4=TT |last5=Frank |first5=AJ |last6=Haapasalo |first6=H |last7=Connelly |first7=M |last8=Wetmore |first8=C |last9=Curran |first9=T |title=ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease |volume=8 |issue=10 |pages=3054–64 |journal=Clinical cancer research : an official journal of the American Association for Cancer Research}}</ref><ref name="Pmid">{{cite journal |pmid=16609018 |year=2006 |last1=Mendrzyk |first1=F |last2=Korshunov |first2=A |last3=Benner |first3=A |last4=Toedt |first4=G |last5=Pfister |first5=S |last6=Radlwimmer |first6=B |last7=Lichter |first7=P |title=Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma |volume=12 |issue=7 Pt 1 |pages=2070–9 |doi=10.1158/1078-0432.CCR-05-2363 |journal=Clinical cancer research : an official journal of the American Association for Cancer Research}}</ref><ref>{{cite journal |pmid=9329458 |year=1997 |last1=Rushing |first1=EJ |last2=Yashima |first2=K |last3=Brown |first3=DF |last4=White Cl |first4=3rd |last5=Shay |first5=JW |last6=Risser |first6=RC |last7=Gazdar |first7=AF |title=Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas |volume=56 |issue=10 |pages=1142–6 |journal=Journal of neuropathology and experimental neurology |doi=10.1097/00005072-199710000-00008}}</ref>  High expression of [[epidermal growth factor receptor]] (''EGFR'') correlates with unfavorable outcome.<ref name="Pmid" /> Over-expression of [[kinetochore]] proteins and down-regulation of [[metallothionein]]s are associated with recurrence in [[ependymoma]]s.<ref>{{cite journal |pmid=20885975 |year=2010 |last1=Peyre |first1=M |last2=Commo |first2=F |last3=Dantas-Barbosa |first3=C |last4=Andreiuolo |first4=F |last5=Puget |first5=S |last6=Lacroix |first6=L |last7=Drusch |first7=F |last8=Scott |first8=V |last9=Varlet |first9=P |title=Portrait of ependymoma recurrence in children: Biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis |volume=5 |issue=9 |pages=e12932 |doi=10.1371/journal.pone.0012932 |pmc=2945762 |journal=PLoS ONE |editor1-last=Jones |editor1-first=Chris}}</ref> [[CD117|KIT]] receptor tyrosine kinase and [[phosphorylation|phospho]]-[[CD117|KIT]] were found to be present in pediatric ependymomas and may be involved in [[angiogenesis]] associated with those tumors.<ref name="Pmid_e">{{cite journal |pmid=20030644 |year=2010 |last1=Puputti |first1=M |last2=Tynninen |first2=O |last3=Pernilä |first3=P |last4=Salmi |first4=M |last5=Jalkanen |first5=S |last6=Paetau |first6=A |last7=Sihto |first7=H |last8=Joensuu |first8=H |title=Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors |volume=20 |issue=4 |pages=763–70 |doi=10.1111/j.1750-3639.2009.00357.x |pmc=2901521 |journal=Brain pathology (Zurich, Switzerland)}}</ref>

===Chromosomal changes===
[[Comparative genomic hybridization]] (CGH) experiments have shown pediatric ependymomas possess a number of [[genomic]] anomalies not seen in adult [[ependymoma]]s.<ref name="Pmid_a">{{cite journal |pmid=19531565 |year=2009 |last1=Kilday |first1=JP |last2=Rahman |first2=R |last3=Dyer |first3=S |last4=Ridley |first4=L |last5=Lowe |first5=J |last6=Coyle |first6=B |last7=Grundy |first7=R |title=Pediatric ependymoma: Biological perspectives |volume=7 |issue=6 |pages=765–86 |doi=10.1158/1541-7786.MCR-08-0584 |journal=Molecular cancer research : MCR}}</ref>  In addition, ependymomas from different locations within the [[central nervous system]] (spinal, [[supratentorial]], and [[infratentorial]]) can be distinguished by their [[chromosomal]], [[immunohistochemistry|immunohistochemical]], and [[gene expression]] differences.<ref name="Pmid_a" />

Amplification of [[chromosome 1q]] and loss of [[chromosome 6|6q]], [[chromosome 17|17p]] and [[chromosome 22|22q]] are the most common numerical chromosomal changes in pediatric ependymomas.<ref name="Pmid_b">{{cite journal |pmid=10459338 |year=1999 |last1=Mazewski |first1=C |last2=Soukup |first2=S |last3=Ballard |first3=E |last4=Gotwals |first4=B |last5=Lampkin |first5=B |title=Karyotype studies in 18 ependymomas with literature review of 107 cases |volume=113 |issue=1 |pages=1–8 |journal=Cancer genetics and cytogenetics |doi=10.1016/S0165-4608(99)00046-1}}</ref><ref>{{cite journal |pmid=10451703 |year=1999 |last1=Reardon |first1=DA |last2=Entrekin |first2=RE |last3=Sublett |first3=J |last4=Ragsdale |first4=S |last5=Li |first5=H |last6=Boyett |first6=J |last7=Kepner |first7=JL |last8=Look |first8=AT |title=Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma |volume=24 |issue=3 |pages=230–7 |doi=10.1002/(SICI)1098-2264(199903)24:3<230::AID-GCC8>3.0.CO;2-C |journal=Genes, chromosomes & cancer}}</ref><ref>{{cite journal |pmid=11477662 |year=2001 |last1=Ward |first1=S |last2=Harding |first2=B |last3=Wilkins |first3=P |last4=Harkness |first4=W |last5=Hayward |first5=R |last6=Darling |first6=JL |last7=Thomas |first7=DG |last8=Warr |first8=T |title=Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma |volume=32 |issue=1 |pages=59–66 |doi=10.1002/gcc.1167 |journal=Genes, chromosomes & cancer}}</ref>  Gain of chromosome 1q (1q21.1-32.1) is more common in the pediatric population and is associated with tumor recurrence in [[intracranial]] ependymomas.  Moreover, gain of chromosome 1q25 has been found to independent [[prognostic]] value for  recurrence-free and overall survival.<ref name="Pmid" /> Loss of [[chromosome 22|22q]] has been found in both [[sporadic cancer|sporadic]] and [[family|familial]] cases, supporting the presence of a [[tumor suppressor gene]] at this location.<ref>{{cite journal |pmid=7931388 |year=1994 |last1=Nijssen |first1=PC |last2=Deprez |first2=RH |last3=Tijssen |first3=CC |last4=Hagemeijer |first4=A |last5=Arnoldus |first5=EP |last6=Teepen |first6=JL |last7=Holl |first7=R |last8=Niermeyer |first8=MF |title=Familial anaplastic ependymoma: Evidence of loss of chromosome 22 in tumour cells |volume=57 |issue=10 |pages=1245–8 |pmc=485495 |journal=Journal of neurology, neurosurgery, and psychiatry |doi=10.1136/jnnp.57.10.1245}}</ref><ref name="Pmid_c">{{cite journal |pmid=8889505 |year=1996 |last1=Von Haken |first1=MS |last2=White |first2=EC |last3=Daneshvar-Shyesther |first3=L |last4=Sih |first4=S |last5=Choi |first5=E |last6=Kalra |first6=R |last7=Cogen |first7=PH |title=Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas |volume=17 |issue=1 |pages=37–44 |doi=10.1002/(SICI)1098-2264(199609)17:1<37::AID-GCC6>3.0.CO;2-3 |journal=Genes, chromosomes & cancer}}</ref>  However, loss of [[chromosome 22|22q]] is more common in the [[ependymoma|adult form]] than pediatric cases.<ref name="Pmid_b" /><ref name="Pmid_c" /><ref>{{cite journal |pmid=9525835 |year=1998 |last1=Kramer |first1=DL |last2=Parmiter |first2=AH |last3=Rorke |first3=LB |last4=Sutton |first4=LN |last5=Biegel |first5=JA |title=Molecular cytogenetic studies of pediatric ependymomas |volume=37 |issue=1 |pages=25–33 |journal=Journal of neuro-oncology |doi=10.1023/A:1005925613992}}</ref> As ''[[NF2 (gene)|NF2]]'' is located on [[chromosome 22|22q12.2]], it was hypothesized to be involved in the development of ependymoma.  Though mutations in ''NF2'' are rarely found in [[sporadic cancer|sporadic]] ependymomas other than the spinal form,<ref name="Pmid_d" /><ref>{{cite journal |pmid=7657387 |year=1995 |last1=Slavc |first1=I |last2=MacCollin |first2=MM |last3=Dunn |first3=M |last4=Jones |first4=S |last5=Sutton |first5=L |last6=Gusella |first6=JF |last7=Biegel |first7=JA |title=Exon scanning for mutations of the NF2 gene in pediatric ependymomas, rhabdoid tumors and meningiomas |volume=64 |issue=4 |pages=243–7 |journal=International Journal of Cancer. Journal International Du Cancer}}</ref> ''SCHIP1'', a ''NF2'' interacting gene, is significantly down-regulated in pediatric ependymomas, supporting a role for the ''NF2'' pathway in the initiation of ependymomas.<ref>{{cite journal |pmid=15701279 |year=2005 |last1=Suarez-Merino |first1=B |last2=Hubank |first2=M |last3=Revesz |first3=T |last4=Harkness |first4=W |last5=Hayward |first5=R |last6=Thompson |first6=D |last7=Darling |first7=JL |last8=Thomas |first8=DG |last9=Warr |first9=TJ |title=Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3 |volume=7 |issue=1 |pages=20–31 |doi=10.1215/S1152851704000596) |pmc=1871622 |journal=Neuro-oncology}}</ref>

===Oncogenes and tumor suppressor genes===
A variety of [[oncogenes]] and [[tumor suppressor gene]]s have been found to be mutated or possess altered expression in pediatric ependymomas.  [[CD117|KIT receptor tyrosine kinase]] and [[phosphorylation|phospho]]-[[CD117|KIT]] have been suggested to play a role in the development of pediatric ependymomas,<ref name="Pmid_e" /> ''[[NOTCH1]]'' mutations have been found in approximately 8% of pediatric ependymomas,<ref name="Pmid_g">{{cite journal |pmid=19289631 |year=2009 |last1=Puget |first1=S |last2=Grill |first2=J |last3=Valent |first3=A |last4=Bieche |first4=I |last5=Dantas-Barbosa |first5=C |last6=Kauffmann |first6=A |last7=Dessen |first7=P |last8=Lacroix |first8=L |last9=Geoerger |first9=B |title=Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas |volume=27 |issue=11 |pages=1884–92 |doi=10.1200/JCO.2007.15.4195 |journal=Journal of clinical oncology : official journal of the American Society of Clinical Oncology}}</ref> and ''[[MEN1]]'' mutations are  occasionally found in pediatric ependymomas.<ref>{{cite journal |pmid=12505253 |year=2002 |last1=Urioste |first1=M |last2=Martínez-Ramírez |first2=A |last3=Cigudosa |first3=JC |last4=Colmenero |first4=I |last5=Madero |first5=L |last6=Robledo |first6=M |last7=Martínez-Delgado |first7=B |last8=Benítez |first8=J |title=Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma |volume=138 |issue=2 |pages=107–10 |journal=Cancer genetics and cytogenetics |doi=10.1016/S0165-4608(01)00532-5}}</ref>  ''[[MMP2]]'' and ''[[MMP14]]'' appear to also play a role in tumor growth and progression in [[intracranial]] cases.<ref name="Pmid_l">{{cite journal |pmid=18716553 |year=2008 |last1=Snuderl |first1=M |last2=Chi |first2=SN |last3=De Santis |first3=SM |last4=Stemmer-Rachamimov |first4=AO |last5=Betensky |first5=RA |last6=De Girolami |first6=U |last7=Kieran |first7=MW |title=Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas |volume=67 |issue=9 |pages=911–20 |doi=10.1097/NEN.0b013e318184f413 |pmc=2686114 |journal=Journal of neuropathology and experimental neurology}}</ref>  Two candidate genes, ''[[TPR (gene)|TPR]]'' and ''CHIBBY'', have been identified on commonly altered [[chromosome]] regions in pediatric ependymomas, [[chromosome 1|chromosomes 1q25]] and [[chromosome 22|chromosome 22q12-q13]].<ref>{{cite journal |pmid=18663750 |year=2008 |last1=Karakoula |first1=K |last2=Suarez-Merino |first2=B |last3=Ward |first3=S |last4=Phipps |first4=KP |last5=Harkness |first5=W |last6=Hayward |first6=R |last7=Thompson |first7=D |last8=Jacques |first8=TS |last9=Harding |first9=B |title=Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13 |volume=47 |issue=11 |pages=1005–22 |doi=10.1002/gcc.20607 |journal=Genes, chromosomes & cancer}}</ref>  Expression of two additional candidate [[gene]]s, ''[[S100A6]]'' and ''[[S100A4]]'' on [[chromosome 1q]] have also been found to correspond to [[supratentorial]] tumor development and tumors occurring before the age of 3 years old, though it is unclear exactly what role these genes play in the [[etiology]].<ref>{{cite journal |pmid=18781180 |year=2008 |last1=Rand |first1=V |last2=Prebble |first2=E |last3=Ridley |first3=L |last4=Howard |first4=M |last5=Wei |first5=W |last6=Brundler |first6=MA |last7=Fee |first7=BE |last8=Riggins |first8=GJ |last9=Coyle |first9=B |title=Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma |volume=99 |issue=7 |pages=1136–43 |doi=10.1038/sj.bjc.6604651 |pmc=2567087 |journal=British journal of cancer}}</ref>

=== Tumor progression ===
Ependymomas have been suggested to arise from [[radial glial cell]]s, suggesting [[neural]] [[stem cell]] maintenance pathways such as [[Notch signaling pathway|Notch]], [[Sonic Hedgehog]] (SHH), and [[p53]] are important for the [[pathogenesis]] of ependymomas.<ref name="Pmid_f" />  

Notch signaling pathway and HOX family of [[transcription factor]]s are up regulated in [[supratentorial]] and [[Vertebral column|spinal]] ependymomas respectively.<ref name="Pmid_f" />  Over-expression of Notch [[ligand]]s, [[Receptor (biochemistry)|receptors]], and target genes (''[[HES1]]'', ''[[HEY2]]'', and ''[[MYC]]''), as well as down-regulation of Notch repressor (Fbxw7) are found in pediatric ependymoma.<ref name="Pmid_g" /> Inhibition of Notch pathway impairs tumor growth ''[[in vitro]]''.<ref name="Pmid_g" /> Notch target [[ErbB2]] is up-regulated in most ependymomas, correlating with poor outcome.<ref name="Pmid_h" />  

While [[p53]] (''[[TP53]]'') mutations are not often observed in pediatric ependymoma,<ref>{{cite journal |pmid=8699232 |year=1996 |last1=Fink |first1=KL |last2=Rushing |first2=EJ |last3=Schold Jr |first3=SC |last4=Nisen |first4=PD |title=Infrequency of p53 gene mutations in ependymomas |volume=27 |issue=2 |pages=111–5 |journal=Journal of neuro-oncology}}</ref> the p53 pathway is suggested to play a role in radiation therapy resistance<ref>{{cite journal |pmid=16086408 |year=2006 |last1=Gaspar |first1=N |last2=Grill |first2=J |last3=Geoerger |first3=B |last4=Lellouch-Tubiana |first4=A |last5=Michalowski |first5=MB |last6=Vassal |first6=G |title=P53 Pathway dysfunction in primary childhood ependymomas |volume=46 |issue=5 |pages=604–13 |doi=10.1002/pbc.20532 |journal=Pediatric blood & cancer}}</ref> and tumor progression,<ref>{{cite journal |pmid=18721229 |year=2009 |last1=Sharma |first1=MC |last2=Ghara |first2=N |last3=Jain |first3=D |last4=Sarkar |first4=C |last5=Singh |first5=M |last6=Mehta |first6=VS |title=A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas |volume=29 |issue=2 |pages=148–55 |doi=10.1111/j.1440-1789.2008.00962.x |journal=Neuropathology : official journal of the Japanese Society of Neuropathology}}</ref> possibly via over-expression of ''[[MDM2]]''.<ref>{{cite journal |pmid=10824927 |year=2000 |last1=Suzuki |first1=SO |last2=Iwaki |first2=T |title=Amplification and overexpression of mdm2 gene in ependymomas |volume=13 |issue=5 |pages=548–53 |doi=10.1038/modpathol.3880095 |journal=Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc}}</ref>  Further, up-regulation of [[p73]] (''[[TP73]]''), a [[homolog]] of [[p53]], and deletion of the p53 pathway gene [[p14arf]]/[[p16 (gene)|p16]]/INK4A (''CDKN2A'') have also been found in pediatric ependymomas.<ref name="Pmid_i" />  

Over-expression of components of [[Sonic hedgehog|SHH]] pathway such as ''[[GLI1]]'', ''[[GLI2]]'', and ''[[STK36]]'' implicates deregulation of the SHH pathway in ependymomas.<ref name="Pmid_i" />  Moreover, over-expression of SHH targets ''[[IGFBP2]]'', ''[[IGFBP3]]'', and ''[[IGFBP5]]'' in ependymoma is also suggestive of a role for SHH and [[insulin-like growth factor]] (IGF) signaling in the [[pathogenesis]] of pediatric ependymomas.<ref>{{cite journal |pmid=18478565 |year=2008 |last1=De Bont |first1=JM |last2=Van Doorn |first2=J |last3=Reddingius |first3=RE |last4=Graat |first4=GH |last5=Passier |first5=MM |last6=Den Boer |first6=ML |last7=Pieters |first7=R |title=Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients |volume=123 |issue=3 |pages=594–600 |doi=10.1002/ijc.23558 |journal=International Journal of Cancer. Journal International Du Cancer}}</ref>

===Rate of progression===
[[Endothelial cell]] [[CD117|KIT]] expression was associated with a young age at diagnosis of [[pilocytic astrocytoma]] or ependymoma.<ref name="Pmid_e" /> [[Telomerase]] activity is found in childhood ependymoma. In addition, [[telomerase]] reactivation and maintenance of [[telomere]]s appears to be required for progression. Low expression of [[nucleolin]], an interacting protein of [[telomerase]], was found to be the single most important biological predictor of outcome, where low expression correlates with a more favorable prognosis.<ref name="Pmid_k">{{cite journal |pmid=18701711 |year=2008 |last1=Ridley |first1=L |last2=Rahman |first2=R |last3=Brundler |first3=MA |last4=Ellison |first4=D |last5=Lowe |first5=J |last6=Robson |first6=K |last7=Prebble |first7=E |last8=Luckett |first8=I |last9=Gilbertson |first9=RJ |title=Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma |volume=10 |issue=5 |pages=675–89 |doi=10.1215/15228517-2008-036 |pmc=2666244 |journal=Neuro-oncology}}</ref>

==Clinical biology==

===Presentation===
[[Symptom]]s present 1–36 months before [[diagnosis]], and can vary depending on age, [[tumor grade]], and location.  Increased [[intracranial pressure]] can induce vomiting, headache, irritability, [[lethargy]], changes in [[gait]], and in children less than 2, feeding problems, involuntary eye movements, and [[hydrocephalus]] are often noticeable.  [[Seizure]]s occur in about 20% of pediatric patients.<ref>{{cite journal |pmid=8943102 |year=1996 |last1=Piepmeier |first1=JM |title=Tumors and approaches to the lateral ventricles. Introduction and overview |volume=30 |issue=3 |pages=267–74 |journal=Journal of neuro-oncology}}</ref><ref>{{cite journal |pmid=9095015 |year=1997 |last1=Shemie |first1=S |last2=Jay |first2=V |last3=Rutka |first3=J |last4=Armstrong |first4=D |title=Acute obstructive hydrocephalus and sudden death in children |volume=29 |issue=4 |pages=524–8 |journal=Annals of Emergency Medicine |doi=10.1016/S0196-0644(97)70227-0}}</ref>  Loss of [[cognitive function]] and even sudden death could occur if the tumor is located at a crucial location for CSF flow.  Pediatric ependymomas most often occur in the [[posterior cranial fossa]], in contrast with adult [[ependymoma]]s which usually occur along the [[Vertebral column|spine]].<ref name="Pmid_j">{{cite journal |pmid=19387655 |year=2009 |last1=Tamburrini |first1=G |last2=D'ercole |first2=M |last3=Pettorini |first3=BL |last4=Caldarelli |first4=M |last5=Massimi |first5=L |last6=Di Rocco |first6=C |title=Survival following treatment for intracranial ependymoma: A review |volume=25 |issue=10 |pages=1303–12 |doi=10.1007/s00381-009-0874-y |journal=Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery}}</ref> Ependymomas present as low-density masses on [[CT scan]]s, and are hyperintense on T2-weighted [[MRI]] images.<ref>{{cite journal |pmid=1919685 |year=1991 |last1=Peretti-Viton |first1=P |last2=Perez Castillo |first2=AM |last3=Martini |first3=P |last4=Margain |first4=D |last5=Murayama |first5=N |title=Supratentorial ependymomas. Neuroradiological study |volume=18 |issue=2 |pages=201–9 |journal=Journal of neuroradiology. Journal de neuroradiologie}}</ref>

===Pathology===
Significant debate remains over [[tumor grade|grading]] of ependymomas,<ref>{{cite journal |pmid=19212775 |year=2009 |last1=Godfraind |first1=C |title=Classification and controversies in pathology of ependymomas |volume=25 |issue=10 |pages=1185–93 |doi=10.1007/s00381-008-0804-4 |journal=Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery}}</ref> though the [[WHO]] 2007 classification lists [[subependymoma]] ([[tumor grade|grade]] I), myxopapillary ependymoma ([[tumor grade|grade I]]), ependymoma ([[tumor grade|grade II]]), and anaplastic ependymoma ([[tumor grade|grade]] IV) as the primary classifications.<ref>{{cite journal |pmid=17618441 |year=2007 |last1=Louis |first1=DN |last2=Ohgaki |first2=H |last3=Wiestler |first3=OD |last4=Cavenee |first4=WK |last5=Burger |first5=PC |last6=Jouvet |first6=A |last7=Scheithauer |first7=BW |last8=Kleihues |first8=P |title=The 2007 WHO classification of tumours of the central nervous system |volume=114 |issue=2 |pages=97–109 |doi=10.1007/s00401-007-0243-4 |pmc=1929165 |journal=Acta Neuropathologica}}</ref>  This classification scheme further designates four subtypes within the ependymoma group.  However, there are several recognized subtypes of ependymoma with differing [[pathology|pathologies]].  These include myxopapillary ependymoma (MEPN) which tend to grow slowly and are restricted to the [[conus medullaris]]-[[cauda equina]]-[[filum terminale]] region of the [[spinal cord]], [[intracranial]], [[infratentorial]] ([[posterior fossa]]{{disambiguation needed|date=March 2012}}), intracranial supratentorial, and [[Vertebral column|spinal]] ependymoma, and subependymomas.  Reports have shown that location-based classification is most relevant to the molecular characteristics, implicating underlying tissue-specificity effects.<ref name="Pmid_f" />

Ependymomas arise from [[oncogenic]] events mutating normal [[ependymal cell]]s into [[cancerous]] cells.  Recent evidence suggests the primary cells are [[radial glia]]. [[Genetics|Genetic]] alterations are fairly heterogeneous among [[histology|histologically]] similar ependymoma tumors.<ref name="Pmid_f" />

===Diagnostic features===
[[Comparative genomic hybridization]] (CGH) experiments have shown pediatric tumors possess a number of [[genomic]] anomalies not seen in adult [[ependymoma]]s, with a high prevalence of whole [[chromosome]] imbalances.<ref name="Pmid_a" /><ref>{{cite journal |pmid=18179864 |year=2008 |last1=Pezzolo |first1=A |last2=Capra |first2=V |last3=Raso |first3=A |last4=Morandi |first4=F |last5=Parodi |first5=F |last6=Gambini |first6=C |last7=Nozza |first7=P |last8=Giangaspero |first8=F |last9=Cama |first9=A |title=Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma |volume=261 |issue=2 |pages=235–43 |doi=10.1016/j.canlet.2007.11.021 |journal=Cancer letters}}</ref> [[Epithelial membrane antigen]] has been shown to help distinguish ependymomas from other pediatric [[Central nervous system|CNS]] tumors.<ref>{{cite journal |pmid=17284108 |year=2007 |last1=Takei |first1=H |last2=Bhattacharjee |first2=MB |last3=Rivera |first3=A |last4=Dancer |first4=Y |last5=Powell |first5=SZ |title=New immunohistochemical markers in the evaluation of central nervous system tumors: A review of 7 selected adult and pediatric brain tumors |volume=131 |issue=2 |pages=234–41 |doi=10.1043/1543-2165(2007)131[234:NIMITE]2.0.CO;2 |journal=Archives of pathology & laboratory medicine |issn=1543-2165}}</ref>  Neuraxis MR imaging and lumbar CSF cytology evaluation are widely accepted methods for determining tumor dissemination.<ref>{{cite journal |pmid=20672933 |year=2010 |last1=Terterov |first1=S |last2=Krieger |first2=MD |last3=Bowen |first3=I |last4=McComb |first4=JG |title=Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas |volume=6 |issue=2 |pages=131–6 |doi=10.3171/2010.5.PEDS09333 |journal=Journal of neurosurgery. Pediatrics}}</ref>

===Differential diagnoses===
Once a tumor is suspected, [[medulloblastoma]]s, diffuse astrocytomas, [[pilocytic astrocytoma]]s, and ependymomas remain in the differential diagnosis as [[posterior fossa]]{{disambiguation needed|date=March 2012}} tumors.  However, only [[pilocytic astrocytoma]]s and ependymomas stain positively for [[Galectin-3]].<ref>{{cite journal |pmid=20711594 |year=2011 |last1=Borges |first1=CB |last2=Bernardes |first2=ES |last3=Latorraca |first3=EF |last4=Becker |first4=AP |last5=Neder |first5=L |last6=Chammas |first6=R |last7=Roque-Barreira |first7=MC |last8=Machado |first8=HR |last9=De Oliveira |first9=RS |title=Galectin-3 expression: A useful tool in the differential diagnosis of posterior fossa tumors in children |volume=27 |issue=2 |pages=253–7 |doi=10.1007/s00381-010-1262-3 |journal=Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery}}</ref>  The subtype of ependymoma can also be narrowed down by molecular means.  For instance, the myxopapillary ependyomas have been found to have higher expression of ''[[HOXB5]]'', ''[[PLA2G5]]'', and ''[[ITIH2]]''.<ref>{{cite journal |pmid=19793339 |year=2010 |last1=Barton |first1=VN |last2=Donson |first2=AM |last3=Kleinschmidt-Demasters |first3=BK |last4=Birks |first4=DK |last5=Handler |first5=MH |last6=Foreman |first6=NK |title=Unique molecular characteristics of pediatric myxopapillary ependymoma |volume=20 |issue=3 |pages=560–70 |doi=10.1111/j.1750-3639.2009.00333.x |pmc=2871180 |journal=Brain pathology (Zurich, Switzerland)}}</ref>  A [[gene expression profiling]] experiment has shown that three members of the ''[[SOX genes|SOX]]'' family of [[transcription factor]]s also possessed discriminatory power between [[medulloblastoma]]s and ependymomas.<ref>{{cite journal |pmid=18577562 |year=2008 |last1=De Bont |first1=JM |last2=Kros |first2=JM |last3=Passier |first3=MM |last4=Reddingius |first4=RE |last5=Sillevis Smitt |first5=PA |last6=Luider |first6=TM |last7=Den Boer |first7=ML |last8=Pieters |first8=R |title=Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis |volume=10 |issue=5 |pages=648–60 |doi=10.1215/15228517-2008-032 |pmc=2666242 |journal=Neuro-oncology}}</ref>  Without [[histology]], it is difficult to differentiate grade II versus grade III anaplastic ependymomas because there are no [[anatomical]] differences on [[magnetic resonance imaging]].<ref>{{cite journal |pmid=21530988 |year=2011 |last1=Martínez León |first1=MI |last2=Vidal Denis |first2=M |last3=Weil Lara |first3=B |title=Magnetic resonance imaging of infratentorial anaplastic ependymoma in children |doi=10.1016/j.rx.2011.01.005 |journal=Radiologia}}</ref>

===Prognostic features===
In general, pediatric ependymomas are associated with less favorable prognoses than adult [[ependymoma]]s, and ependymomas of younger pediatric patients are less favorable than ependymomas of older pediatric patients (reviewed in <ref name="Pmid_j" />).  Tumors that occur in the [[posterior fossa]]{{disambiguation needed|date=March 2012}} have also been shown to have a less favorable prognosis.<ref>{{cite journal |pmid=9705591 |year=1998 |last1=Sala |first1=F |last2=Talacchi |first2=A |last3=Mazza |first3=C |last4=Prisco |first4=R |last5=Ghimenton |first5=C |last6=Bricolo |first6=A |title=Prognostic factors in childhood intracranial ependymomas: The role of age and tumor location |volume=28 |issue=3 |pages=135–42 |journal=Pediatric neurosurgery |doi=10.1159/000028637}}</ref>  Expression of ''[[TERT]]'' in pediatric [[intracranial]] ependymomas is correlated with [[telomerase]] activity and tumor progression and negatively correlated with survival.<ref>{{cite journal |pmid=16575002 |year=2006 |last1=Tabori |first1=U |last2=Ma |first2=J |last3=Carter |first3=M |last4=Zielenska |first4=M |last5=Rutka |first5=J |last6=Bouffet |first6=E |last7=Bartels |first7=U |last8=Malkin |first8=D |last9=Hawkins |first9=C |title=Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma |volume=24 |issue=10 |pages=1522–8 |doi=10.1200/JCO.2005.04.2127 |journal=Journal of clinical oncology : official journal of the American Society of Clinical Oncology}}</ref> The protein [[nucleolin]] and expression of ''[[MMP2]]'' and ''[[MMP14]]'' have been found to inversely correlate with progression free survival in cases of pediatric ependymoma, though RTK-1 family members were not correlated.<ref name="Pmid_l" /><ref name="Pmid_k" /> Tumor microinvasion, even in tumors appearing well-demarcated using various imaging modalities, was also found to be inversely associated with|progression-free and overall survival.<ref name="Pmid_l" /> Some evidence suggests [[chromosome 6|chromosome 6q25.3]] deletion may provide additional survival benefit in pediatric ependymomas.<ref>{{cite journal |pmid=18328946 |year=2008 |last1=Monoranu |first1=CM |last2=Huang |first2=B |last3=Zangen |first3=IL |last4=Rutkowski |first4=S |last5=Vince |first5=GH |last6=Gerber |first6=NU |last7=Puppe |first7=B |last8=Roggendorf |first8=W |title=Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas |volume=182 |issue=1 |pages=18–26 |doi=10.1016/j.cancergencyto.2007.12.008 |journal=Cancer genetics and cytogenetics}}</ref>

===Treatment===
[[Chemotherapy]] regimens for pediatric ependymomas have produced only modest benefit and degree of resection remains the most  conspicuous factor in recurrence and survival.<ref>{{cite journal |pmid=19212772 |year=2009 |last1=Wright |first1=KD |last2=Gajjar |first2=A |title=New chemotherapy strategies and biological agents in the treatment of childhood ependymoma |volume=25 |issue=10 |pages=1275–82 |doi=10.1007/s00381-009-0809-7 |pmc=2738756 |journal=Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery}}</ref><ref>{{cite journal |pmid=19458954 |year=2009 |last1=Shim |first1=KW |last2=Kim |first2=DS |last3=Choi |first3=JU |title=The history of ependymoma management |volume=25 |issue=10 |pages=1167–83 |doi=10.1007/s00381-009-0900-0 |journal=Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery}}</ref><ref>{{cite journal |pmid=19153750 |year=2009 |last1=Little |first1=AS |last2=Sheean |first2=T |last3=Manoharan |first3=R |last4=Darbar |first4=A |last5=Teo |first5=C |title=The management of completely resected childhood intracranial ependymoma: The argument for observation only |volume=25 |issue=3 |pages=281–4 |doi=10.1007/s00381-008-0799-x |journal=Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery}}</ref><ref>{{cite journal |pmid=2262372 |year=1990 |last1=Goldwein |first1=JW |last2=Leahy |first2=JM |last3=Packer |first3=RJ |last4=Sutton |first4=LN |last5=Curran |first5=WJ |last6=Rorke |first6=LB |last7=Schut |first7=L |last8=Littman |first8=PS |last9=D'angio |first9=GJ |title=Intracranial ependymomas in children |volume=19 |issue=6 |pages=1497–502 |journal=International journal of radiation oncology, biology, physics |doi=10.1016/0360-3016(90)90362-N}}</ref><ref>{{cite journal |pmid=18084249 |year=2008 |last1=Tihan |first1=T |last2=Zhou |first2=T |last3=Holmes |first3=E |last4=Burger |first4=PC |last5=Ozuysal |first5=S |last6=Rushing |first6=EJ |title=The prognostic value of histological grading of posterior fossa ependymomas in children: A Children's Oncology Group study and a review of prognostic factors |volume=21 |issue=2 |pages=165–77 |doi=10.1038/modpathol.3800999 |journal=Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc}}</ref>  

The association of ''[[TERT]]'' expression with poor outcome in pediatric ependymomas has driven some researchers to suggest that [[telomerase]] inhibition may be an effective [[adjuvant therapy]] for pediatric ependymomas.  Further, data from ''in vitro'' experiments using primary tumor isolate cells suggest that inhibition of [[telomerase]] activity may inhibit cell proliferation and increase sensitivity of cells to [[DNA]] damaging agents,<ref>{{cite journal |pmid=20184588 |year=2010 |last1=Wong |first1=VC |last2=Morrison |first2=A |last3=Tabori |first3=U |last4=Hawkins |first4=CE |title=Telomerase inhibition as a novel therapy for pediatric ependymoma |volume=20 |issue=4 |pages=780–6 |doi=10.1111/j.1750-3639.2010.00372.x |journal=Brain pathology (Zurich, Switzerland)}}</ref> consistent with the observation of high [[telomerase]] activity in primary tumors.<ref name="Pmid_k" /> Additionally, because apurinic/apyrimidinic endonuclease (''APE1'') has been found to confer radiation resistance in pediatric ependymomas, it has been suggested that inhibitors of Ap endo activity might also restore [[radiotherapy|radiation]] sensitivity.<ref>{{cite journal |pmid=21207372 |year=2011 |last1=Bobola |first1=MS |last2=Jankowski |first2=P |last3=Gross |first3=ME |last4=Schwartz |first4=J |last5=Finn |first5=LS |last6=Blank |first6=A |last7=Ellenbogen |first7=RG |last8=Silber |first8=JR |title=Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma |doi=10.1002/ijc.25900 |journal=International Journal of Cancer. Journal International Du Cancer |pages=n/a–n/a |volume=129 |issue=10}}</ref>

Within the infratentorial group of pediatric ependymomas, [[radiotherapy]] was found to significantly increase 5-year survival.<ref>{{cite journal |pmid=19006249 |year=2009 |last1=McGuire |first1=CS |last2=Sainani |first2=KL |last3=Fisher |first3=PG |title=Both location and age predict survival in ependymoma: A SEER study |volume=52 |issue=1 |pages=65–9 |doi=10.1002/pbc.21806 |journal=Pediatric blood & cancer}}</ref> However, a retrospective review of sterotactic radiosurgery showed it provided only a modest benefit to patients who had previously undergone resection and radiation.<ref>{{cite journal |pmid=21039163 |year=2010 |last1=Kano |first1=H |last2=Yang |first2=HC |last3=Kondziolka |first3=D |last4=Niranjan |first4=A |last5=Arai |first5=Y |last6=Flickinger |first6=JC |last7=Lunsford |first7=LD |title=Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas |volume=6 |issue=5 |pages=417–23 |doi=10.3171/2010.8.PEDS10252 |journal=Journal of neurosurgery. Pediatrics}}</ref> Though other supratentorial tumors tend to have a better prognosis, supratentorial anaplastic ependymomas are the most aggressive ependymoma and neither total excision nor postoperative irradiation was found to be effective in preventing early recurrence.<ref>{{cite journal |pmid=17786000 |year=2007 |last1=Kumar |first1=R |last2=Singhal |first2=N |last3=Jaiswal |first3=SK |last4=Mahapatra |first4=AK |title=Recurrence in supratentorial anaplastic ependymoma |volume=43 |issue=5 |pages=364–8 |doi=10.1159/000106384 |journal=Pediatric neurosurgery}}</ref>

Following resection of infratentorial ependymomas, residual tumor is more likely in lateral versus medial tumors, classified radiologically pre-operatively.<ref>{{cite journal |pmid=20680298 |year=2010 |last1=U-King-Im |first1=JM |last2=Taylor |first2=MD |last3=Raybaud |first3=C |title=Posterior fossa ependymomas: New radiological classification with surgical correlation |volume=26 |issue=12 |pages=1765–72 |doi=10.1007/s00381-010-1251-6 |journal=Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery}}</ref><ref name="Pmid_m">{{cite journal |pmid=19360422 |year=2009 |last1=Shimoji |first1=K |last2=Miyajima |first2=M |last3=Karagiozov |first3=K |last4=Yatomi |first4=K |last5=Matsushima |first5=T |last6=Arai |first6=H |title=Surgical considerations in fourth ventricular ependymoma with the transcerebellomedullary fissure approach in focus |volume=25 |issue=10 |pages=1221–8 |doi=10.1007/s00381-009-0835-5 |journal=Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery}}</ref>  Specific techniques, such as cerebellomedullary fissure dissection have been proposed to aid in complete resection while avoiding [[iatrogenic]] effects in these cases.<ref name="Pmid_m" /> Surveillance neuroimaging for recurrence provides additional survival to patients over observation alone.<ref>{{cite journal |pmid=11147894 |year=2001 |last1=Good |first1=CD |last2=Wade |first2=AM |last3=Hayward |first3=RD |last4=Phipps |first4=KP |last5=Michalski |first5=AJ |last6=Harkness |first6=WF |last7=Chong |first7=WK |title=Surveillance neuroimaging in childhood intracranial ependymoma: How effective, how often, and for how long? |volume=94 |issue=1 |pages=27–32 |doi=10.3171/jns.2001.94.1.0027 |journal=Journal of neurosurgery}}</ref>

===Biochemical markers===
[[hTERT]] and [[H2AFX|yH2AX]] are crucial markers for prognosis and response to therapy. High [[hTERT]] and low [[H2AFX|yH2AX]] expression is associated with poor response to therapy.  Patients with both high or low expression of these markers make up the moderate response groups.<ref name="Pmid_o">{{cite journal |pmid=18797459 |year=2008 |last1=Tabori |first1=U |last2=Wong |first2=V |last3=Ma |first3=J |last4=Shago |first4=M |last5=Alon |first5=N |last6=Rutka |first6=J |last7=Bouffet |first7=E |last8=Bartels |first8=U |last9=Malkin |first9=D |title=Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma |volume=99 |issue=7 |pages=1129–35 |doi=10.1038/sj.bjc.6604652 |pmc=2567068 |journal=British journal of cancer}}</ref>

===Relapse===
The 5-year disease-free survival for age >5 years is 50-60%.<ref name="Pmid_n">{{cite journal |pmid=10080027 |year=1997 |last1=Sanford |first1=RA |last2=Gajjar |first2=A |title=Ependymomas |volume=44 |pages=559–70 |journal=Clinical neurosurgery}}</ref>  Another report found a similar 5-year survival at about 65% with 51% progression-free survival.<ref>{{cite journal |pmid=15770637 |year=2005 |last1=Agaoglu |first1=FY |last2=Ayan |first2=I |last3=Dizdar |first3=Y |last4=Kebudi |first4=R |last5=Gorgun |first5=O |last6=Darendeliler |first6=E |title=Ependymal tumors in childhood |volume=45 |issue=3 |pages=298–303 |doi=10.1002/pbc.20212 |journal=Pediatric blood & cancer}}</ref> The 10-year disease-free survival is 40-50%.  Younger ages showed lower 5 and 10-year survival rates.<ref name="Pmid_n" /> A 2006 study that observed 133 patients found 31 (23.3%) had a recurrence of the disease within a five-year period.<ref name="Pmid_o" />

===Long-term consequences of treatment===
Use of [[telomerase]] inhibitors such as Imetelstat seem to have very low toxicity compared to other [[chemotherapy]].  The only known side effect of most [[telomerase]] inhibitors is dose-induced [[neutropenia]].<ref>{{cite journal |pmid=21208905 |year=2011 |last1=Castelo-Branco |first1=P |last2=Zhang |first2=C |last3=Lipman |first3=T |last4=Fujitani |first4=M |last5=Hansford |first5=L |last6=Clarke |first6=I |last7=Harley |first7=CB |last8=Tressler |first8=R |last9=Malkin |first9=D |title=Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition |volume=17 |issue=1 |pages=111–21 |doi=10.1158/1078-0432.CCR-10-2075 |journal=Clinical cancer research : an official journal of the American Association for Cancer Research}}</ref>  Neuropsychological deficits can result from resection,<ref>{{cite journal |pmid=10775548 |year=2000 |last1=Levisohn |first1=L |last2=Cronin-Golomb |first2=A |last3=Schmahmann |first3=JD |title=Neuropsychological consequences of cerebellar tumour resection in children: [[Cerebellar cognitive affective syndrome]] in a paediatric population |volume=123 |pages=1041–50 |journal=Brain : a journal of neurology |issue=5}}</ref> [[chemotherapy]],<ref>{{cite journal |pmid=21157347 |year=2011 |last1=Winick |first1=N |title=Neurocognitive outcome in survivors of pediatric cancer |volume=23 |issue=1 |pages=27–33 |doi=10.1097/MOP.0b013e32834255e9 |journal=Current Opinion in Pediatrics}}</ref> and radiation, as well as [[endocrinopathies]].<ref>{{cite journal |pmid=21037539 |year=2010 |last1=Mostoufi-Moab |first1=S |last2=Grimberg |first2=A |title=Pediatric brain tumor treatment: Growth consequences and their management |volume=8 |issue=1 |pages=6–17 |journal=Pediatric endocrinology reviews : PER}}</ref>  Additionally, an increase in [[gastrointestinal]] complications has been observed in survivors of pediatric cancers.<ref>{{cite journal |pmid=21315721 |year=2011 |last1=Goldsby |first1=R |last2=Chen |first2=Y |last3=Raber |first3=S |last4=Li |first4=L |last5=Diefenbach |first5=K |last6=Shnorhavorian |first6=M |last7=Kadan-Lottick |first7=N |last8=Kastrinos |first8=F |last9=Yasui |first9=Y |title=Survivors of childhood cancer have increased risk of gastrointestinal complications later in life |volume=140 |issue=5 |pages=1464–71.e1 |doi=10.1053/j.gastro.2011.01.049 |pmc=3081911 |journal=Gastroenterology}}</ref>

==References==
{{Reflist|2}}

== External links ==
* [http://www.cancer.gov/cancertopics/pdq/treatment/childependymoma/Patient/page1| National Cancer Institute website] 
* [http://wiki.medpedia.com/Childhood_Ependymoma wiki.medpedia.com]
* [http://emedicine.medscape.com/article/986333-overview emedicine.medscape.com]
* [http://www.cern-foundation.org/Content.aspx?id=608 cern-foundation.org]
* [http://www.childrenshospital.org/az/Site841/mainpageS841P0.html childrenshospital.org]
* [http://atlasgeneticsoncology.org/Tumors/EpendymomID5016.html atlasgeneticsoncology.org]
* [http://www.cancer.net/patient/Cancer+Types/Ependymoma+-+Childhood cancer.net]
* [http://www.umgcc.org/brain_tumor_center/brain-child-epend.htm umgcc.org]
* [http://rad.usuhs.edu/medpix/cow_image.html?pt_id=11784&imageid=41184&quiz=no MedPix] Imaging and Diagnosis

[[Category:Articles created via the Article Wizard]]
[[Category:Types of cancer]]
[[Category:Brain tumor]]
[[Category:Medical treatments]]
[[Category:Pediatric cancers]]